4DX Share Price Performance
AU$1.44
0.92 (175.96%)
21.0% undervalued intrinsic discount
AU$1.82
Fair Value
Price AU$1.44
AnalystConsensusTarget AU$1.82
Fair ValueAU$1.82
Share PriceAU$1.44
21.0% undervalued intrinsic discount
4DMedical Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 39 Fair Values set on narratives written by author
4DX Community Narratives
AN
Fair Value AU$1.82 21.0% undervalued intrinsic discount
Recent Regulatory Wins And Reimbursement Approvals Will Drive Broader Market Access
0users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
Recent Regulatory Wins And Reimbursement Approvals Will Drive Broader Market Access
Key Takeaways Strategic acquisitions, partnerships, and regulatory approvals are poised to enhance market presence, revenue, and net margins through expanded distribution and high-margin services. Geographic expansion and new technology development aim to increase market penetration, scan volumes, and capture significant market share, improving overall financial performance.Read more
0users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
AN
AU$1.82
21.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
115.18% p.a.
Profit Margin
4.56%
Future PE
516.64x
Share price in 2028
AU$1.64
Snowflake Analysis
4DMedical Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.059
- 92.07%
- -513.72%
- 0%
About 4DX
- Founded
- 2012
- Employees
- 124
- CEO
- WebsiteView website
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company was incorporated in 2012 and is based in Carlton, Australia.
